reglab/housing_qa huggingface dataset:
CA Health & Safety Code § 122476 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 105 - COMMUNICABLE DISEASE PREVENTION AND CONTROL|PART 7.7 - Valley Fever|Section 122476.

122476.  (a) Valley fever, also called coccidioidomycosis, is a lung infection caused by a fungus that lives in the soil. Approximately 10,000 cases are reported each year, mostly from California and bordering states.(b) Valley fever is a serious, costly illness. According to the federal Centers for Disease Control and Prevention, nearly 75 percent of people with valley fever miss work or school. As many as 40 percent of people who get valley fever need to stay in the hospital.(c) People get valley fever by breathing in microscopic fungal spores from the air in areas where the fungus lives. Anyone who lives in or travels to these areas can get valley fever, but some people are at higher risk for developing valley fever, such as older adults, people who have weakened immune systems, pregnant women, people with diabetes, people who are Black or Filipino, and people who have jobs that expose them to dust, such as agricultural or construction workers.(d) The symptoms of valley fever are similar to those of other common illnesses, so patients may have delays in getting diagnosed and treated. The initial symptoms may appear one to three weeks after exposure. They tend to resemble those of the flu, and can range from minor to severe, including fever, cough, chest pain, chills, night sweats, headache, fatigue, joint aches, and a red spotty rash.(e) In areas with valley fever, it is difficult to completely avoid exposure to the fungus because it is in the environment. There is no vaccine to prevent infection. Knowing about valley fever is one of the most important ways to avoid delays in diagnosis and treatment.(f) It is the intent of the Legislature to raise awareness of the symptoms, tests, and treatments for valley fever among the general public, primary health care providers, and health care providers who care for persons at higher risk for getting valley fever.(Added by Stats. 2018, Ch. 338, Sec. 1. (AB 1790) Effective January 1, 2019.)
CA Health & Safety Code § 124300 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 3 - FAMILY PLANNING|Section 124300.

124300.  Within any county where 10 percent or more of the population, as determined by the Demographic Research Unit of the Department of Finance, speaks any one language other than English as its native language, every local health department shall make copies of circulars and pamphlets relating to family planning that are made available to the public also available in the other language.The State Department of Health Care Services, upon request, shall make a translation available in other than English those family planning informational materials normally distributed to the general public.(Amended by Stats. 2019, Ch. 29, Sec. 122. (SB 82) Effective June 27, 2019.)
CA Health & Safety Code § 124960 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 4.5 - PAIN PATIENT'S BILL OF RIGHTS|Section 124960.

124960.  The Legislature finds and declares all of the following:(a) The state has a right and duty to control the illegal use of opiate drugs.(b) Inadequate treatment of acute and chronic pain originating from cancer or noncancerous conditions is a significant health problem.(c) For some patients, pain management is the single most important treatment a physician can provide.(d) A patient suffering from severe chronic intractable pain should have access to proper treatment of his or her pain.(e) Due to the complexity of their problems, many patients suffering from severe chronic intractable pain may require referral to a physician with expertise in the treatment of severe chronic intractable pain. In some cases, severe chronic intractable pain is best treated by a team of clinicians in order to address the associated physical, psychological, social, and vocational issues.(f) In the hands of knowledgeable, ethical, and experienced pain management practitioners, opiates administered for severe acute pain and severe chronic intractable pain can be safe.(g) Opiates can be an accepted treatment for patients in severe chronic intractable pain who have not obtained relief from any other means of treatment.(h) A patient suffering from severe chronic intractable pain has the option to request or reject the use of any or all modalities to relieve his or her pain.(i) A physician treating a patient who suffers from severe chronic intractable pain may prescribe a dosage deemed medically necessary to relieve pain as long as the prescribing is in conformance with Section 2241.5 of the Business and Professions Code.(j) A patient who suffers from severe chronic intractable pain has the option to choose opiate medication for the treatment of the severe chronic intractable pain as long as the prescribing is in conformance with Section 2241.5 of the Business and Professions Code.(k) The patient’s physician may refuse to prescribe opiate medication for a patient who requests the treatment for severe chronic intractable pain. However, that physician shall inform the patient that there are physicians who treat severe chronic intractable pain with methods that include the use of opiates.(Amended by Stats. 2011, Ch. 396, Sec. 2. (AB 507) Effective January 1, 2012.)
CA Health & Safety Code § 124961 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 4.5 - PAIN PATIENT'S BILL OF RIGHTS|Section 124961.

124961.  Nothing in this section shall be construed to alter any of the provisions set forth in Section 2241.5 of the Business and Professions Code. This section shall be known as the Pain Patient’s Bill of Rights.(a) A patient who suffers from severe chronic intractable pain has the option to request or reject the use of any or all modalities in order to relieve his or her pain.(b) A patient who suffers from severe chronic intractable pain has the option to choose opiate medications to relieve that pain without first having to submit to an invasive medical procedure, which is defined as surgery, destruction of a nerve or other body tissue by manipulation, or the implantation of a drug delivery system or device, as long as the prescribing physician acts in conformance with the California Intractable Pain Treatment Act, Section 2241.5 of the Business and Professions Code.(c) The patient’s physician may refuse to prescribe opiate medication for the patient who requests a treatment for severe chronic intractable pain. However, that physician shall inform the patient that there are physicians who treat pain and whose methods include the use of opiates.(d) A physician who uses opiate therapy to relieve severe chronic intractable pain may prescribe a dosage deemed medically necessary to relieve the patient’s pain, as long as that prescribing is in conformance with Section 2241.5 of the Business and Professions Code.(e) A patient may voluntarily request that his or her physician provide an identifying notice of the prescription for purposes of emergency treatment or law enforcement identification.(f) Nothing in this section shall do either of the following:(1) Limit any reporting or disciplinary provisions applicable to licensed physicians and surgeons who violate prescribing practices or other provisions set forth in the Medical Practice Act, Chapter 5 (commencing with Section 2000) of Division 2 of the Business and Professions Code, or the regulations adopted thereunder.(2) Limit the applicability of any federal statute or federal regulation or any of the other statutes or regulations of this state that regulate dangerous drugs or controlled substances.(Amended by Stats. 2011, Ch. 396, Sec. 3. (AB 507) Effective January 1, 2012.)
CA Health & Safety Code § 125850 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 106 - PERSONAL HEALTH CARE (INCLUDING MATERNAL, CHILD, AND ADOLESCENT)|PART 10 - MALE CIRCUMCISION|Section 125850.

125850.  (a) The Legislature finds and declares as follows:(1) Male circumcision has a wide array of health and affiliative benefits.(2) This section clarifies existing law.(b) No city, county, or city and county ordinance, regulation, or administrative action shall prohibit or restrict the practice of male circumcision, or the exercise of a parent’s authority to have a child circumcised.(c) The Legislature finds and declares that the laws affecting male circumcision must have uniform application throughout the state. Therefore, this part shall apply to general law and charter cities, general law and charter counties, and charter city and counties.(Added by Stats. 2011, Ch. 398, Sec. 1. (AB 768) Effective October 2, 2011.)
CA Health & Safety Code § 130500 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 112 - CALIFORNIA DISCOUNT PRESCRIPTION DRUG PROGRAM|CHAPTER 1 - General Provisions|Section 130500.

130500.  (a) This division shall be known, and may be cited, as the California Discount Prescription Drug Program.(b) This division shall become operative on and after July 1, 2010.(c) The California Discount Prescription Drug Program shall be implemented only if, and to the extent that, a Budget Act or other statute that is enacted on or before February 1, 2015, includes or makes an appropriation of moneys to the department to implement this program.(d) Notwithstanding any other provision of this division, if the California Discount Prescription Drug Program is not implemented pursuant to subdivision (c), this division shall become inoperative on February 1, 2015, and as of January 1, 2016, is repealed, unless a later enacted statute, that is enacted before January 1, 2016, deletes or extends the dates on which it becomes inoperative and is repealed.(Amended by Stats. 2010, Ch. 717, Sec. 22. (SB 853) Effective October 19, 2010. Repealed conditionally on January 1, 2016, by its own provisions. Note: Control provisions in this section relate to operation, implementation, and termination of Division 112, comprising Sections 130500 to 130544.)
CA Health & Safety Code § 130502 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 112 - CALIFORNIA DISCOUNT PRESCRIPTION DRUG PROGRAM|CHAPTER 1 - General Provisions|Section 130502.

130502.  The California Discount Prescription Drug Program is hereby established within the department.(Added by Stats. 2006, Ch. 619, Sec. 2. Effective January 1, 2007. Provisions operative and implemented on or after July 1, 2010, as prescribed in Section 130500. Conditionally inoperative on February 1, 2015. Repealed conditionally on January 1, 2016, pursuant to Section 130500.)
CA Health & Safety Code § 130505 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 112 - CALIFORNIA DISCOUNT PRESCRIPTION DRUG PROGRAM|CHAPTER 2 - Prescription Drug Discounts|Section 130505.

130505.  (a) The amount a participating, eligible Californian pays for a drug through the program shall be equal to the lower of the participating pharmacy’s usual and customary charge or the pharmacy contract rate pursuant to subdivision (c), less a program discount for the specific drug or an average discount for a group of drugs or all drugs covered by the program.(b) In determining program discounts on individual drugs, the department shall take into account the rebates provided by the drug’s manufacturer.(c) The department may contract with participating pharmacies for a rate other than the pharmacies’ usual and customary rate for prescription drugs, including multiple-source drugs.(d) This division shall apply only to prescription drugs dispensed to eligible Californians on an outpatient basis.(Added by Stats. 2006, Ch. 619, Sec. 2. Effective January 1, 2007. Provisions operative and implemented on or after July 1, 2010, as prescribed in Section 130500. Conditionally inoperative on February 1, 2015. Repealed conditionally on January 1, 2016, pursuant to Section 130500.)
CA Health & Safety Code § 130507 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 112 - CALIFORNIA DISCOUNT PRESCRIPTION DRUG PROGRAM|CHAPTER 2 - Prescription Drug Discounts|Section 130507.

130507.  (a) On August 1, 2017, the department shall determine whether manufacturer participation in the program has been sufficient to meet both of the following benchmarks:(1) The number and type of drugs available through the program are sufficient to give eligible Californians a formulary comparable to the Medi-Cal list of contract drugs or, if this information is available to the department, a formulary comparable to that provided to CalPERS enrollees.(2) The volume weighted average discount of single-source prescription drugs offered pursuant to this program is equal to or below any one of the benchmark prices described in subdivision (a) of Section 130506.(b) On and after August 1, 2017, the department shall reassess program outcomes, at least once every year, consistent with the benchmarks described in subdivision (a).(Amended by Stats. 2010, Ch. 717, Sec. 23. (SB 853) Effective October 19, 2010. Provisions operative and implemented on or after July 1, 2010, as prescribed in Section 130500. Conditionally inoperative on February 1, 2015. Repealed conditionally on January 1, 2016, pursuant to Section 130500.)
CA Health & Safety Code § 130508 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 112 - CALIFORNIA DISCOUNT PRESCRIPTION DRUG PROGRAM|CHAPTER 2 - Prescription Drug Discounts|Section 130508.

130508.  To the maximum extent possible, the department shall assure that enrollment and other administrative actions are seamless to all eligible Californians.(Added by Stats. 2006, Ch. 619, Sec. 2. Effective January 1, 2007. Provisions operative and implemented on or after July 1, 2010, as prescribed in Section 130500. Conditionally inoperative on February 1, 2015. Repealed conditionally on January 1, 2016, pursuant to Section 130500.)
CA Health & Safety Code § 130509 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 112 - CALIFORNIA DISCOUNT PRESCRIPTION DRUG PROGRAM|CHAPTER 2 - Prescription Drug Discounts|Section 130509.

130509.  (a) The department may require prior authorization in the Medi-Cal program for any drug of a manufacturer if the manufacturer fails to agree to a volume weighted average discount for single-source prescription drugs that is equal to or below any one of the benchmark prices described in subdivision (a) of Section 130506 and only to the extent that this requirement does not increase costs to the Medi-Cal program, as determined pursuant to subdivision (c).(b) If prior authorization is required for a drug pursuant to this section, a Medi-Cal beneficiary shall not be denied the continued use of a drug that is part of a prescribed therapy until that drug is no longer prescribed for that beneficiary’s therapy. The department shall approve or deny requests for prior authorization necessitated by this section as required by state or federal law.(c) The department, in consultation with the Department of Finance, shall determine the fiscal impact of placing a drug on prior authorization pursuant to this section. In making this determination, the department shall consider all of the following:(1) The net cost of the drug, including any rebates that would be lost if the drug is placed on prior authorization.(2) The projected volume of purchases of the drug, before and after the drug is placed on prior authorization, considering the continuity of care provisions set forth in subdivision (b).(3) The net cost of comparable drugs to which volume would be shifted if a drug is placed on prior authorization, including any additional rebates that would be received.(4) The projected volume of purchases of comparable drugs, before and after the drug is placed on prior authorization.(5) Any other factors determined by the department to be relevant to a determination of the fiscal impact of placing a drug on prior authorization.(d) This section shall be implemented only to the extent permitted under federal law, and in a manner consistent with state and federal laws.(e) This section may apply to any manufacturer that has not negotiated with the department.(f) The department shall notify the Speaker of the Assembly and the President pro Tempore of the Senate that the department is requiring prior authorization no later than five days after making this requirement.(g) (1) Subject to paragraph (2), this section shall be implemented on and after August 1, 2017.(2) This section shall be implemented only if the department determines that participation by manufacturers has been insufficient to meet both of the benchmarks identified in Section 130507.(Amended by Stats. 2010, Ch. 717, Sec. 24. (SB 853) Effective October 19, 2010. Provisions operative and implemented on or after July 1, 2010, as prescribed in Section 130500. Conditionally inoperative on February 1, 2015. Repealed conditionally on January 1, 2016, pursuant to Section 130500.)
CA Health & Safety Code § 130510 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 112 - CALIFORNIA DISCOUNT PRESCRIPTION DRUG PROGRAM|CHAPTER 2 - Prescription Drug Discounts|Section 130510.

130510.  The names of manufacturers of single-source drugs that do or do not enter into discount agreements with the department pursuant to this division shall be public information and shall be posted on the department’s Internet Web site when the discount agreements are reached or the manufacturer ends negotiations, commencing within six months after the initial implementation date of this division and updated on the first of each month thereafter.(Added by Stats. 2006, Ch. 619, Sec. 2. Effective January 1, 2007. Provisions operative and implemented on or after July 1, 2010, as prescribed in Section 130500. Conditionally inoperative on February 1, 2015. Repealed conditionally on January 1, 2016, pursuant to Section 130500.)
CA Health & Safety Code § 130511 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 112 - CALIFORNIA DISCOUNT PRESCRIPTION DRUG PROGRAM|CHAPTER 2 - Prescription Drug Discounts|Section 130511.

130511.  (a) Each drug discount agreement shall do all of the following:(1) Specify which of the manufacturer’s drugs are included in the agreement.(2) Permit the department to remove a drug from the agreement if there is a dispute over the drug’s utilization.(3) Permit a manufacturer to audit claims for the drugs the manufacturer provides under the program. Claims information provided to manufacturers shall comply with all federal and state privacy laws that protect a program participant’s health information.(b) In addition to the requirements of subdivision (a), each drug discount agreement with a single-source manufacturer shall do all of the following:(1) Require the manufacturer to make a rebate payment to the department for each drug described in paragraph (1) of subdivision (a) dispensed to a program participant.(2) Require the manufacturer to make the rebate payments to the department on at least a quarterly basis.(3) Require the manufacturer to provide, upon request, documentation to validate the rebate.(c) The department may collect prospective rebates from single-source manufacturers for payment to pharmacies. The amount of the prospective discount shall be specified in the drug rebate agreements.(d) (1) Manufacturers shall calculate and pay interest on late or unpaid rebates. The interest shall not apply to any prior period adjustments of unit rebate amounts or department utilization adjustments.(2) For rebate payments to the program, manufacturers shall calculate and pay interest on late or unpaid rebates for quarters that begin on or after January 1, 2007.(e) Interest required by subdivision (d) shall begin accruing 38 calendar days from the date of mailing of the invoice, including supporting utilization data sent to the manufacturer. Interest shall continue to accrue until the date of mailing of the manufacturer’s payment. Interest rates and calculations for purposes of this section shall be at 10 percent.(f) A participating manufacturer shall clearly identify all rebates, interest, and other payments, and payment transmittal forms for the program, in a manner designated by the department.(Added by Stats. 2006, Ch. 619, Sec. 2. Effective January 1, 2007. Provisions operative and implemented on or after July 1, 2010, as prescribed in Section 130500. Conditionally inoperative on February 1, 2015. Repealed conditionally on January 1, 2016, pursuant to Section 130500.)
CA Health & Safety Code § 130512 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 112 - CALIFORNIA DISCOUNT PRESCRIPTION DRUG PROGRAM|CHAPTER 2 - Prescription Drug Discounts|Section 130512.

130512.  (a) The department shall generate a monthly report that, at a minimum, provides all of the following:(1) Drug utilization information.(2) Amounts paid to pharmacies.(3) Program discounts compared to the usual customary price.(4) Aggregate amounts of rebates collected from manufacturers.(5) A summary of the problems or complaints reported regarding the program.(b) Information provided in paragraphs (1), (2), and (3) of subdivision (a) shall be at the national drug code level.(c) The department shall generate an annual report that, in addition to the information described in subdivision (a), reports on the number of all of the following:(1) Individuals enrolled.(2) Individuals receiving a prescription under the program.(3) Participating pharmacies.(4) Participating manufacturers.(d) All reports shall be made available on the department’s Internet Web site.(Added by Stats. 2006, Ch. 619, Sec. 2. Effective January 1, 2007. Provisions operative and implemented on or after July 1, 2010, as prescribed in Section 130500. Conditionally inoperative on February 1, 2015. Repealed conditionally on January 1, 2016, pursuant to Section 130500.)
CA Health & Safety Code § 130513 (2021)
2021 California Code|Health and Safety Code - HSC|DIVISION 112 - CALIFORNIA DISCOUNT PRESCRIPTION DRUG PROGRAM|CHAPTER 2 - Prescription Drug Discounts|Section 130513.

130513.  (a) The department shall establish and maintain a claims processing system that complies with all of the following requirements:(1) Charges a price that meets the requirements of this division.(2) Provides the pharmacy with the dollar amount of the discount to be returned to the pharmacy.(3) Provides drug utilization review warnings to pharmacies consistent with the drug utilization review standards provided in federal law.(b) The department shall pay a participating pharmacy the discount provided to program participants pursuant to this division by a date that is not later than two weeks after the claim is received.(c) The department shall develop a mechanism for the program participants to report problems or complaints.(Added by Stats. 2006, Ch. 619, Sec. 2. Effective January 1, 2007. Provisions operative and implemented on or after July 1, 2010, as prescribed in Section 130500. Conditionally inoperative on February 1, 2015. Repealed conditionally on January 1, 2016, pursuant to Section 130500.)